Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Populus Deltoides Subsp. Monilifera Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of IgE-mediated allergies to Eastern Cottonwood pollen through skin testing and subcutaneous immunotherapy.
Name
Populus Deltoides Subsp. Monilifera Pollen
Raw Name
POPULUS DELTOIDES SUBSP. MONILIFERA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
21
Variant Count
23
Last Verified
February 17, 2026
About Populus Deltoides Subsp. Monilifera Pollen
Populus Deltoides Subsp. Monilifera Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of IgE-mediated allergies to Eastern Cottonwood pollen through skin testing and subcutaneous immunotherapy.
Detailed information about Populus Deltoides Subsp. Monilifera Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Populus Deltoides Subsp. Monilifera Pollen.
Populus Deltoides Subsp. Monilifera Pollen, commonly known as Eastern Cottonwood pollen, is a biological substance used primarily in the field of clinical allergy and immunology. It belongs to the pharmacological class of Non-Standardized Pollen Allergenic Extracts [EPC]. This extract is derived from the male catkins of the Populus deltoides tree, specifically the monilifera subspecies, which is widely distributed across North America, particularly in the Great Plains and eastern regions. In clinical practice, this extract is utilized for two primary purposes: the diagnostic identification of specific allergic sensitivities (via skin prick or intradermal testing) and the therapeutic desensitization of patients through allergen immunotherapy (AIT), often referred to as 'allergy shots.'
As a non-standardized extract, the potency of Populus Deltoides Subsp. Monilifera Pollen is typically expressed in terms of weight/volume (w/v) ratio or Protein Nitrogen Units (PNU), rather than Bioequivalent Allergy Units (BAU). This distinction is critical for healthcare providers to understand, as it implies that the biological activity may vary between different manufacturing lots, necessitating careful titration when switching vials. The FDA has historically regulated these extracts under the Public Health Service Act, ensuring that they meet rigorous standards for purity and identity, even while the 'standardized' label is reserved for extracts with more precise potency measurements (such as grasses or ragweed).
Healthcare providers classify this agent as a tool for managing Type I hypersensitivity reactions. When a patient is exposed to Eastern Cottonwood pollen in the environment, their immune system may produce IgE antibodies that bind to mast cells. Subsequent exposure triggers the release of inflammatory mediators like histamine. The therapeutic use of this extract aims to modify this immune response over time, shifting the body's reaction from one of inflammation to one of tolerance.
The mechanism of action for Populus Deltoides Subsp. Monilifera Pollen extract is multifaceted, involving both the innate and adaptive immune systems. When used for diagnostic skin testing, the extract introduces a small amount of the allergen directly into the skin. If the patient has pre-existing IgE antibodies specific to Eastern Cottonwood pollen, these antibodies—which are 'sensitized' on the surface of mast cells—will cross-link with the pollen proteins. This cross-linking causes mast cell degranulation, releasing histamine, leukotrienes, and prostaglandins, which results in a 'wheal and flare' reaction (a raised bump and surrounding redness) within 15 to 20 minutes.
In the context of allergen immunotherapy (AIT), the mechanism is a long-term process of 'desensitization.' By administering gradually increasing doses of the pollen extract subcutaneously, the healthcare provider induces a series of immunological changes:
Traditional pharmacokinetic studies (absorption, distribution, metabolism, and excretion) are challenging to apply to allergenic extracts because they are complex mixtures of proteins rather than single chemical entities. However, the clinical behavior of these extracts can be described through their immunological processing.
Populus Deltoides Subsp. Monilifera Pollen extract is FDA-approved for the following indications:
Off-label uses are rare, though some specialists may use the extract in research settings to study cross-reactivity between different members of the Salicaceae family (which includes other poplars and willows).
This extract is typically available in the following formats:
> Important: Only your healthcare provider can determine if Populus Deltoides Subsp. Monilifera Pollen is right for your specific condition.
Dosage for Populus Deltoides Subsp. Monilifera Pollen is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity level and clinical history. There is no 'standard' dose for all patients.
Populus Deltoides Subsp. Monilifera Pollen extract is generally considered safe for use in children, typically those aged 5 years and older. Use in children under age 5 requires extreme caution because younger children may have difficulty communicating the early symptoms of a systemic reaction (anaphylaxis). The dosing logic for children is identical to that for adults—based on individual sensitivity rather than weight—though the healthcare provider may choose a more conservative build-up schedule to ensure safety.
No specific dosage adjustments are required for patients with renal impairment, as the proteins in the extract are not cleared by the kidneys in a manner that would lead to toxicity. However, the patient's overall health should be stable before administration.
No dosage adjustments are necessary for patients with hepatic impairment. The metabolism of allergenic proteins does not rely on the cytochrome P450 system or other hepatic metabolic pathways.
Geriatric patients may require more cautious dosing, primarily due to the higher prevalence of comorbid conditions such as cardiovascular disease. If an elderly patient is taking beta-blockers or ACE inhibitors, the risk of a severe reaction to the extract (and the difficulty of treating it) is increased. Providers may choose a slower build-up phase for these individuals.
This medication is never self-administered. It must be given by a healthcare professional in a clinical setting equipped to handle anaphylaxis.
If a dose is missed during the build-up phase, the healthcare provider may need to repeat the previous dose or even reduce the dose, depending on how much time has passed. If more than 4 weeks have passed since the last dose, a significant reduction in the next dose is usually required to prevent a systemic reaction due to loss of tolerance.
An 'overdose' in the context of allergenic extracts usually refers to a dosage error where a patient receives a higher concentration than intended. This is a medical emergency.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
The most frequent side effects associated with Populus Deltoides Subsp. Monilifera Pollen are local reactions at the site of the injection or skin test. These are generally considered a sign that the immune system is responding to the allergen.
These reactions are more significant and may require a dosage adjustment for the next scheduled injection.
These side effects are uncommon but indicate a higher level of systemic sensitivity.
> Warning: Stop taking Populus Deltoides Subsp. Monilifera Pollen and call your doctor immediately if you experience any of these.
There are no known long-term 'toxic' side effects of Populus Deltoides Subsp. Monilifera Pollen extract, as it is a natural protein. Unlike corticosteroids or other allergy medications, it does not cause weight gain, bone loss, or organ damage. The primary long-term risk is the development of a new sensitivity to a different component of the extract, though this is rare. Most patients find that the long-term effect is a significant reduction in allergy symptoms and a decreased need for other medications.
While not all non-standardized extracts carry a formal 'Black Box' in the same way as synthetic drugs, the FDA-approved labeling for all allergenic extracts contains a 'Boxed Warning' regarding the risk of severe systemic reactions.
Summary of Warning:
Report any unusual symptoms to your healthcare provider.
Populus Deltoides Subsp. Monilifera Pollen extract is a potent biological agent. Its use is restricted to diagnostic and therapeutic protocols under the direct supervision of an allergist or immunologist. The most critical safety consideration is the prevention and management of anaphylaxis. Patients must be in their 'baseline' state of health before receiving an injection; for example, if a patient is currently experiencing an acute asthma flare or a severe viral infection, the injection should be postponed.
No FDA black box warnings exist for Populus Deltoides Subsp. Monilifera Pollen in the traditional sense, but it carries a standard Boxed Warning for all allergenic extracts. This warning emphasizes that the extract can cause anaphylaxis and must only be administered in settings where emergency resuscitation equipment and trained personnel are immediately available. It also notes that the risk is higher in patients with pre-existing respiratory disease.
Unlike many medications, Populus Deltoides Subsp. Monilifera Pollen does not require routine blood work (like liver or kidney function tests). Instead, monitoring is clinical:
Most patients can drive or operate machinery after the 30-minute observation period. However, if a patient experiences any dizziness, lightheadedness, or 'brain fog' after the injection, they should avoid these activities until the symptoms have completely resolved.
There is no direct chemical interaction between alcohol and the pollen extract. However, alcohol can cause vasodilation (widening of blood vessels), which may theoretically increase the speed of allergen absorption and the severity of a systemic reaction. It is advisable to avoid alcohol for several hours before and after an injection.
Immunotherapy is typically a 3-to-5-year commitment. Stopping the treatment prematurely may result in the return of allergy symptoms. If a patient decides to discontinue, there is no 'withdrawal syndrome,' but the immunological tolerance will gradually fade. If a patient stops for several months and wishes to restart, they must begin the build-up phase from the lowest dose again.
> Important: Discuss all your medical conditions with your healthcare provider before starting Populus Deltoides Subsp. Monilifera Pollen.
There are no drugs that are strictly 'contraindicated' in the sense of a chemical reaction, but there are medications that make the use of Populus Deltoides Subsp. Monilifera Pollen unacceptably dangerous:
There are no known food interactions with Populus Deltoides Subsp. Monilifera Pollen extract. However, patients with a 'pollen-food allergy syndrome' (Oral Allergy Syndrome) may notice that eating certain raw fruits (like apples or peaches) during the peak of cottonwood season increases their overall 'allergic load,' potentially making them more sensitive to their injections.
There are no documented interactions with common supplements like St. John's Wort or Ginkgo. However, patients should avoid any herbal 'immune boosters' (like Echinacea) that claim to stimulate the immune system, as the goal of immunotherapy is to modulate the immune system toward a state of tolerance, not stimulation.
The administration of this extract will directly affect:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Populus Deltoides Subsp. Monilifera Pollen extract must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the physician:
Patients allergic to Populus Deltoides Subsp. Monilifera Pollen may also show sensitivity to:
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Populus Deltoides Subsp. Monilifera Pollen.
Populus Deltoides Subsp. Monilifera Pollen is classified as Pregnancy Category C. This means there are no adequate and well-controlled studies in pregnant women.
It is generally considered safe to continue Populus Deltoides Subsp. Monilifera Pollen immunotherapy while breastfeeding. The allergenic proteins and the IgG antibodies produced by the mother are not known to pass into breast milk in any amount that would harm the infant. In fact, maternal IgG4 may even be protective.
Immunotherapy is widely used in the pediatric population.
In patients over age 65, the decision to use Populus Deltoides Subsp. Monilifera Pollen extract must be individualized.
There are no specific restrictions for patients with kidney disease. The extract components are proteins that do not accumulate in the presence of reduced glomerular filtration rate (GFR).
Liver disease does not affect the safety or efficacy of Populus Deltoides Subsp. Monilifera Pollen extract. The 'metabolism' of the allergen occurs through local cellular pathways rather than the liver's detoxification systems.
> Important: Special populations require individualized medical assessment.
Populus Deltoides Subsp. Monilifera Pollen extract works by inducing immunological tolerance. At the molecular level, the allergens (proteins) are captured by dendritic cells. These cells process the proteins into peptides and present them via MHC Class II molecules to naive T-cells. In the presence of the extract's repeated administration, these T-cells differentiate into Regulatory T-cells (Tregs). These Tregs produce IL-10, which has several effects: it suppresses the Th2 response, inhibits mast cell degranulation, and signals B-cells to switch production from IgE to IgG4. IgG4 acts as a 'blocking antibody,' preventing the allergen from binding to IgE on mast cells and basophils.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Local) |
| Protein Binding | Primarily to IgE and IgG4 antibodies |
| Half-life | Days (as processed by immune cells) |
| Tmax | 15–30 minutes (for local reaction) |
| Metabolism | Proteolytic degradation by APCs |
| Excretion | Not renally excreted in intact form |
Populus Deltoides Subsp. Monilifera Pollen is a Non-Standardized Pollen Allergenic Extract. It belongs to the broader class of Antigenic Substances. Related medications include standardized extracts (like Short Ragweed or Timothy Grass) and other non-standardized tree extracts (like Oak or Maple).
Common questions about Populus Deltoides Subsp. Monilifera Pollen
This extract is primarily used for the diagnosis and treatment of allergies to the Eastern Cottonwood tree. In diagnostic settings, it is used in skin prick tests to confirm if a patient is allergic to this specific pollen. For treatment, it is used in allergen immunotherapy (allergy shots) to help the body build a tolerance over time. This can significantly reduce symptoms like sneezing, itchy eyes, and asthma flares caused by cottonwood pollen. It is an essential tool for patients who do not find enough relief from standard over-the-counter allergy medications.
The most common side effects are local reactions at the site where the extract was injected or applied. These include redness, itching, and a raised bump or swelling, similar to a mosquito bite. These reactions usually appear within minutes and fade within a few hours. Some patients may also experience 'late-phase' swelling that appears several hours later and lasts for a day or two. While these are common, any reaction that involves the whole body, such as hives or trouble breathing, is serious and requires immediate medical attention.
It is generally recommended to avoid alcohol on the days you receive an injection of Populus Deltoides Subsp. Monilifera Pollen. Alcohol causes your blood vessels to dilate, which could theoretically speed up the absorption of the allergen into your bloodstream and increase the risk of a systemic reaction. Furthermore, alcohol can sometimes mask the early symptoms of an allergic reaction, such as feeling flushed or dizzy. To ensure maximum safety, most allergists suggest waiting at least several hours after your injection before consuming any alcoholic beverages. Always follow the specific advice of your healthcare provider regarding lifestyle restrictions during immunotherapy.
The safety of this extract during pregnancy depends on whether you are just starting the treatment or are already on a maintenance dose. Doctors usually do not start a new 'build-up' phase of immunotherapy during pregnancy because of the risk of a severe allergic reaction, which could deprive the baby of oxygen. However, if you are already on a stable maintenance dose and are tolerating it well, your doctor may recommend continuing the shots. This helps keep your allergy and asthma symptoms controlled, which is also important for a healthy pregnancy. Always inform your allergist immediately if you become pregnant while receiving these injections.
Allergen immunotherapy is a slow process and not a 'quick fix' for allergy symptoms. Most patients begin to notice a decrease in their allergy symptoms after 6 to 12 months of consistent weekly injections. Significant improvement is usually seen by the second year of treatment. To achieve long-lasting results that persist even after the shots are stopped, a full course of 3 to 5 years of treatment is typically required. It is important to continue using your regular allergy medications as needed during the initial build-up phase of the therapy.
Yes, you can stop the injections at any time without experiencing physical withdrawal symptoms like you might with some other medications. However, stopping the treatment before the recommended 3-to-5-year period usually means your allergy symptoms will eventually return. The 'tolerance' your immune system has built up will gradually fade away. If you miss several doses and then decide to restart, you cannot simply pick up where you left off; your doctor will likely need to lower your dose and slowly build it back up to ensure your safety.
If you miss a scheduled injection, you should contact your allergist's office as soon as possible to reschedule. Do not try to 'double up' on your next dose. The safety of immunotherapy depends on the regular timing of the injections. If you miss only one week, your doctor might give you your usual dose. However, if you miss several weeks, your immune system's tolerance may have decreased, and your doctor will need to reduce the dose for your next injection to prevent a reaction. Consistency is the key to both the safety and success of this treatment.
No, Populus Deltoides Subsp. Monilifera Pollen extract does not cause weight gain. It is a biological extract consisting of natural proteins, not a hormone or a steroid. Unlike oral corticosteroids (like prednisone), which can cause weight gain and other metabolic changes, allergen immunotherapy works solely on the immune system's response to pollen. Any changes in weight you experience while on this treatment are likely due to other factors and should be discussed with your primary care physician. Many patients actually find they feel better and are more active once their allergy symptoms are under control.
Most common medications, like vitamins, birth control, and cholesterol drugs, do not interact with this pollen extract. However, certain medications can make the treatment more dangerous. Specifically, beta-blockers (used for blood pressure or heart issues) can prevent epinephrine from working if you have a severe allergic reaction. ACE inhibitors and certain antidepressants may also increase the risk of a reaction. It is vital that you provide your allergist with a complete list of all medications you are taking, including over-the-counter supplements, before starting immunotherapy.
The concept of 'generic' drugs does not apply to allergenic extracts in the same way it does to pills. These are biological products, and while different companies may manufacture 'Eastern Cottonwood Pollen Extract,' they are not considered identical or interchangeable. Each manufacturer's extract may have slightly different protein concentrations. Therefore, if your doctor switches you from one manufacturer's extract to another, they will often reduce your dose slightly and then build it back up to ensure you can tolerate the new formulation safely.